Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Atyr Pharma Inc’s stock clocked out at $0.87, down -2.48% from its previous closing price of $0.89. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 3.61 million shares were traded. ATYR stock price reached its highest trading level at $0.9239 during the session, while it also had its lowest trading level at $0.866.
Ratios:
To gain a deeper understanding of ATYR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.63 and its Current Ratio is at 5.63. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On September 15, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $1.
Leerink Partners Downgraded its Outperform to Market Perform on September 15, 2025, while the target price for the stock was maintained at $1.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 08 ’25 when SCHIMMEL PAUL bought 682,001 shares for $0.90 per share. The transaction valued at 612,437 led to the insider holds 1,095,024 shares of the business.
SCHIMMEL PAUL bought 317,999 shares of ATYR for $299,364 on Oct 09 ’25. The Director now owns 1,413,023 shares after completing the transaction at $0.94 per share. On Mar 17 ’25, another insider, Gross Jane A, who serves as the Director of the company, bought 3,750 shares for $4.00 each. As a result, the insider paid 15,000 and bolstered with 9,750 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATYR now has a Market Capitalization of 84856424 and an Enterprise Value of 16999426.
Stock Price History:
The Beta on a monthly basis for ATYR is 0.81, which has changed by -0.7188312 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, ATYR has reached a high of $7.29, while it has fallen to a 52-week low of $0.68. The 50-Day Moving Average of the stock is -62.08%, while the 200-Day Moving Average is calculated to be -76.63%.
Shares Statistics:
It appears that ATYR traded 10.87M shares on average per day over the past three months and 4598650 shares per day over the past ten days. A total of 97.99M shares are outstanding, with a floating share count of 94.81M. Insiders hold about 3.24% of the company’s shares, while institutions hold 63.62% stake in the company. Shares short for ATYR as of 1760486400 were 36142593 with a Short Ratio of 3.32, compared to 1757894400 on 33089093. Therefore, it implies a Short% of Shares Outstanding of 36142593 and a Short% of Float of 44.12.
Earnings Estimates
The market rating of Atyr Pharma Inc (ATYR) is currently shaped by the ongoing analysis conducted by 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.06 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.59 and -$0.85 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.59, with 11.0 analysts recommending between -$0.22 and -$1.23.
